Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... trained personnel, and detection dogs to safeguard airports ... revolutionary new electronic chip with nano-sized chemical sensors ... , The groundbreaking nanotechnology-inspired sensor, devised by Prof. ... of Chemistry and Center for Nanoscience and Nanotechnology, ... up the scent of explosives molecules better than ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Clarient, Inc.,(Nasdaq: CLRT ), a premier anatomic ... and the pharmaceutical industry,today announced that, effective June ... join Clarient as Senior Vice President and Chief,Financial ... experience as a public,company CFO in life sciences ...
... 28 Sequenom, Inc. (Nasdaq:,SQNM) today announced that a live audio ... investor briefing event,"Sequenom: The Future of Noninvasive Prenatal Diagnostics." Details of ... Sequenom: The Future of Noninvasive Prenatal Diagnostics, When: ... time, Where: http://www.sequenom.com , Agenda: ...
... 28 SoluLinK, Inc., a leader in,next-generation ... announce the,introduction of a new product, NanoLink(TM) ... highest biotin-binding,capacity of any commercially available polymer-encapsulated ... for high throughput robotic applications where high ...
Cached Biology Technology:Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 2Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 4Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 5Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3 2SoluLinK Introduces NanoLink(TM) Streptavidin Magnetic Microspheres 2
(Date:7/24/2014)... molecules, which have similar counterparts in humans, affect the ... nerve signals into the hippocampus, an area of the ... and the creation of memories. The results of the ... . , Brain function depends on the active communication ... neurons are woven together into a dense network where ...
(Date:7/24/2014)... For years, researchers and patients have hoped that ... type in the bodycould provide insight into numerous diseases ... has been hampered by the inability to transfer research ... counterparts, in part because human ESCs are "primed" and ... Thorold Theunissen, Benjamin Powell, and Haoyi Wang, who are ...
(Date:7/24/2014)... of researchers led by the University of York has ... in the Western Indian Ocean. , The results, ... to a revolution in the management of marine protected ... than 11,000 km in the region now under ... zones of the seas and coasts designed to protect ...
Breaking Biology News(10 mins):A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2Western Indian Ocean communities play vital role in conservation 2
... nation that stretches from coast to coast to coast. But ... climate change? Yves Glinas, associate professor in Concordia,s Department of ... element: iron. In a study published in Nature ... and graduate Alexandre Ouellet, as well as McGill colleague Alfonso ...
... 14, 2012 The latest episode in the American ... podcast series describes the development of a new test ... Amid concerns about the threat of terrorist attacks, ... and other nations. One such team has developed a ...
... March 14, 2012 UC Irvine researchers have discovered how ... that causes major gastrointestinal distress in humans, thrives in the ... it. Their findings help explain why Salmonella ... possible treatments. Most people infected with Salmonella suffer ...
Cached Biology News:Fielding questions about climate change 2New test could help track down and prosecute terrorists 2UCI-led study uncovers how Salmonella avoids the body's immune response 2
... Western Blot Recycling Kit is effective ... blots that have been developed with ... isotopes. It is not recommended for ... etc.), as it is not possible ...
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
Biology Products: